Beijin Biotech Announces Full Production of Phase II Production Base

On December 11, 2021, with the 100,000-liter powder media production line officially put into operation, Shanghai BioEngine Sci-Tech Co., LTD (BioEngine) announced the full production of its Phase II production base, Shanghai Beijin Biotech Co., Ltd (Beijin), a wholly owned subsidiary of BioEngine, is mainly responsible for the localization of various culture media manufacturing business. The completion and production of Beijin will greatly enhance BioEngine's supply and service capability of domestic culture media, and become an important milestone for BioEngine on the way of "Intelligent Manufacturing in China" culture media.

Phase II production base of BioEngine covers an area of nearly 10,000 square meters and is equipped with four fully imported low-temperature needle mill powder media production lines of 100, 1,000, 10,000, and 100,000 liters and one fully automatic liquid media aseptic production line, with an annual production capacity of 55 million liters of powder media and 250,000 liters of liquid media, realizing the consistency of process amplification and production, providing domestic and foreign biopharmaceutical R&D institutions and It provides strong support for the timely and stable supply of key raw materials for domestic and foreign biopharmaceutical R&D institutions and manufacturing enterprises.

BioEngine Phase II production base fully implements information construction, following the implementation guidelines of quality by design, uniqueness of information sources, and standardization among systems, and putting online the five systems of PLM, QMS, ERP, MES, and LIMS to achieve smooth, efficient and orderly production management. In addition to the quality system construction to meet the GMP requirements, it also meets the requirements of EU and US FDA regulations for the registration and declaration of culture media products, providing high-quality culture media for the production of antibodies, vaccines, cell therapy, and other biopharmaceutical products.

The commissioning ceremony of the Phase II production base of BioEngine was held in Shanghai Zhangjiang Jinshan Biomedical Park, where Zhai Jinguo, member of the Party Group of Shanghai Jinshan District People's Government, Li Tao, Vice President of East China University of Science and Technology, Qin Liang, Secretary of Shanghai Science and Technology Venture Capital Co. Ltd. and Dong Tao, Executive Vice President of Shandong Xinde Technology Co., Ltd. delivered speeches at the production ceremony and witnessed the development of Bechtel Biologicals into a new stage together with the guests.

Mr. Tan Wen Song, the founder and chairman of Bechtel Biotech, shared his thoughts on the founding of BioEngine and his commitment to providing high-quality "Intelligent Manufacturing in China" products and technologies to the Chinese and global biopharmaceutical industries.

"In his speech, Mr. Liu Xuping, President of BioEngine, mentioned that BioEngine has invested a large amount of money in innovation and R&D, the quality system in line with international standards, and the establishment of a sustainable and stable supply chain over the years, and believes that "doing the right thing, though slow We believe that "doing the right thing is slow but fast".

According to KeYu Shi, Vice President of BioEngine and General Manager of Beijin, Beijin is not only advanced in culture media capacity and production process in China, but also strict accordance with ISO13485:2016, MDSAP, and GMP, and has fully realized LIMS informational quality inspection and MES production management, which not only provides customers with cost-effective, stable and reliable domestic culture media products but also provides customers with the best quality products. We not only provide customers with cost-effective, stable, and reliable domestic culture media products, but also provide reliable quality inspection data to help customers go abroad and realize the dual reporting of biopharmaceutical products in the US and China. The full-scale production of Be-Jin Biologicals means that we are one step closer to a world-class intelligent culture media factory!

The full production of the Phase II production base is a new starting point for BioEngine's development. BioEngine will set out again to build a new power of cell culture with 30 years of craftsmanship, to empower the development of China and the global biopharmaceutical industry with "Intelligent Manufacturing in China", and to create a bright future for the biopharmaceutical industry of our country together with our partners as always!